Clinical Trial Update: A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate [Phase 1]

View source ↗

Summary

Phase 1 study evaluating radiopharmaceutical 177Lu-DTPA-SC16.56 in neuroendocrine carcinomas of the lung and prostate; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma of the Lung
• Neuroendocrine Carcinoma of the Prostate
• Neuroendocrine Tumor of the Lung

Drugs mentioned

• 177Lu-DTPA-SC16.56

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroendocrine Tumor of the Lung, Neuroendocrine Carcinoma of Lung | Phase 1 | Status: NOT_YET_RECRUITING